Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12066298 | 0.95 | NPC1 (0.57) | NPC1RAB9AATMPOLBMAP4K4 | |
| SCHEMBL3758619 | 0.89 | NPC1 (0.57) | NPC1RAB9AATMPOLBMAP4K4 | |
| SCHEMBL5863738 | 0.89 | L3MBTL1 (0.56) | NPC1RAB9AATMPOLBMAP4K4 | |
| SCHEMBL621869 | 0.87 | POLB (0.71) | NPC1RAB9AATMPOLBMAP4K4 | |
| SCHEMBL6301076 | 0.86 | NPC1 (0.57) | NPC1RAB9AATMKMT2ASMN1; SMN2 | |
| SCHEMBL14526559 | 0.82 | RAB9A (0.52) | NPC1RAB9AATMPOLBMAP4K4 | |
| SCHEMBL9565396 | 0.81 | LMNA (0.50) | NPC1RAB9AATMMAP4K4KMT2A | |
| SCHEMBL21249304 | 0.80 | LMNA (0.58) | NPC1RAB9AKMT2AGAASMN1; SMN2 | |
| SCHEMBL27939013 | 0.80 | LMNA (0.49) | NPC1RAB9AATMMAP4K4KMT2A | |
| SCHEMBL21000116 | 0.80 | HDAC8 (0.57) | NPC1RAB9AATMPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828332-B2 | Non-peptide BDNF neurotrophin mimetics | PharmatorophiX, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828332-B2 | Non-peptide BDNF neurotrophin mimetics | PharmatorophiX, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828330-B2 | Non-peptide BDNF neurotrophin mimetics | PHARMATROPHIX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828330-B2 | Non-peptide BDNF neurotrophin mimetics | PHARMATROPHIX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160046559-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046559-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160023990-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160023990-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20140296343-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140296343-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20120004310-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004310-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023990-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | BDNF, NTRK2, NGF | NPC1 1511/4885RAB9A 2056/4885ATM 4067/4885 |
| US-20120004310-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | BDNF, NTRK2, NGF | NPC1 1511/4885RAB9A 2056/4885ATM 4067/4885 |
| US-20160046559-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | NTRK2, BDNF, NTRK1 | NPC1 1967/4885RAB9A 2162/4885ATM 3233/4885 |
| US-20140296343-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | BDNF, NTRK2, NGF | NPC1 1511/4885RAB9A 2056/4885ATM 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.